Nasonex: profile and news

Itchy, runny misery blows in early Feb 28, 2006
...dramatically, he said. Beyond that, nasal steroid sprays like Flonase, Nasonex and others can work wonders, he said. Drugs like ... - Albuquerque Tribune,

New Survey Shows Europeans' Allergy Symptoms Are Most Severe in ... Feb 14, 2006
Products from the company's research efforts include the CLARITIN(R) (loratadine) family of nonsedating antihistamines, NASONEX(R) (mometasone furoate ... - PR Newswire UK (press release),

NJ/IABC Celebrates Communications Excellence at Annual IRIS Awards ... Feb 3, 2006
...accepted the Communications Management Best in Show award for Schering-Plough's NasonExpert "Breaking Through the Congested Media for NASONEX" Public Relations ... - PR Newswire (press release),

Schering-Plough swings to profit Jan 30, 2006
...said Monday it swung to a profit, helped by sales of Remicade, Peg-Intron, Nasonex and Temodar, though it fell shy of analysts' expectations. ... - Investor's Business Daily (subscription)

Schering-Plough swings to profit Jan 30, 2006
...said Monday it swung to a profit, helped by sales of Remicade, Peg-Intron, Nasonex and Temodar, though fell shy of analysts' expectations. ... - MarketWatch

Schering-Plough Seen Challenged By Generics in 2006 Jan 30, 2006
...loss of 3 cents. The analyst attributed the year-over-year gain to sales in Nasonex, PEG-Intron and Remicade. He also cited “sharply ... - Forbes

Speed the Plough Jan 30, 2006
...is still the largest single contributor and continues to grow (up 19% this quarter), while other drugs like PEG-Intron, Rebetol, Temodar, and Nasonex all also ... - MSNBC

Schering-Plough Reports Financial Results for 2005 Fourth Quarter ... Jan 30, 2006
Citing the growth of key products such as REMICADE, PEG-INTRON, NASONEX and TEMODAR, Hassan said, "Schering-Plough is building product depth and strength. ... - PR Newswire (press release),

Schering-Plough Swings to Profit Jan 30, 2006
Hassan said. Fourth quarter sales growth was driven by prescription pharmaceuticals, Peg-Intron, Rebetol, Nasonex and Remicade. The ... - TheStreet.com

Schering-Plough posts profit, key drugs deliver Jan 30, 2006
...billion -- about $50 million less than Wall Street expectations -- fueled by growth of Peg-Intron, arthritis drug Remicade, allergy drug Nasonex and Temodar ... - Reuters

Earnings Preview: Schering-Plough Jan 27, 2006
Rauch expects earnings per share of 9 cents with sales of $2.5 billion for the quarter, with strong sales of Vytorin, and allergy medicines Nasonex and Clarinex ... - BusinessWeek

UPDATE 1-Schering-Plough posts 4th-qtr profit vs loss Jan 30, 2006
...global sales rose 6 percent to $2.3 billion, fueled by growth of arthritis drug Remicade, hepatitis C treatment Peg-Intron, allergy drug Nasonex and Temodar ... - Reuters

Schering-Plough profit up on drug strength Jan 30, 2006
...the company said. Schering-Plough said its Remicade, Peg-Intron, Nasonex and Temodar drugs also posted growth. Remicade, a rheumatoid ... - BusinessWeek

Schering-Plough posts profit on drug sales Jan 30, 2006
Hassan said hepatitis drug Peg-Intron, allergy inhalant Nasonex and Temodar capsules for certain brain tumors also posted growth. ... - BusinessWeek

S&P 500 Hot Stocks Jan 30, 2006
SGP: sentiment, chart, options) announced that it returned to profitability in the fourth quarter, thanks to sales of Remicade, Peg-Intron, Nasonex, and Temodar ... - Schaeffers Research,

US stocks to open lower; Exxon Mobil up on earnings Jan 30, 2006
Schering-Plough Corp. (SGP) is likely to be an early focus after it swung to a profit, helped by sales of Remicade, PegIntron, Nasonex and Temodar, though fell ... - Investor's Business Daily (subscription)

US stocks open higher, buoyed by Exxon earnings Jan 30, 2006
Schering-Plough Corp. (SGP) was down 34 cents at $19.74 after it swung to a profit, helped by sales of Remicade, PegIntron, Nasonex and Temodar, though it fell ... - Investor's Business Daily (subscription)

US stocks edge higher on strong Exxon Mobil earnings Jan 30, 2006
...(SGP) was down 33 cents at $19.75 after it swung to a profit, helped by sales of Remicade, PegIntron, Nasonex and Temodar, though it fell shy of analysts ... - Investor's Business Daily (subscription)

US stocks close mixed as rate jitters hit Dow Jan 30, 2006
...(SGP) closed down 2.5% at $19.57 after it swung to a profit, helped by sales of Remicade, PegIntron, Nasonex and Temodar, but fell shy of analysts' expectations ... - Investor's Business Daily (subscription)

Schaeffer's Daily Market Blog Features Amylin Pharmaceuticals ... Jan 30, 2006
This morning, Schering-Plough (NYSE:SGP) announced that sales of Remicade, Peg-Intron, Nasonex, and Temodar helped it post a profit in the fourth quarter. ... - Business Wire (press release),

Schering-Plough swings to profit in Q4 Jan 31, 2006
...a launch in Japan; the Crohn's disease and arthritis drug Remicade (infliximab), which jumped 19% to $251 million; the allergy drug Nasonex (mometasone furoate ... - Pharma Times (subscription),

Schering's Nasonex proves effective against nasal congestion Nov 9, 2005
Studies have shown that Schering-Plough's Nasonex provides effective relief from nasal congestion associated with allergic rhinitis. ... - Pharmaceutical Business Review

Data Show Nasal Congestion is Most Bothersome Symptom of Allergic ... Nov 8, 2005
NASONEX(R) (mometasone furoate monohydrate) Nasal Spray, 50 mcg* provides effective relief of nasal congestion associated with allergic rhinitis, according to ... - PR Newswire (press release),

Data Show Nasal Congestion is Most Bothersome Symptom of Allergic ... Nov 8, 2005
According to an analysis of pooled data from four clinical studies presented at the meeting, NASONEX(R) (mometasone furoate monohydrate) provides effective ... - PR Newswire (press release),

Once-Daily Asthma Inhaler Approved Nov 30, 2005
...in a statement. The active ingredient is the same one used in Schering-Plough’s Nasonex, a nasal allergy spray. In clinical trials ... - PakTribune.com,

Schaeffer's Midday Options Update Features Schering-Plough ... Nov 22, 2005
SGP is best known for its allergy treatments, Clarinex and Nasonex. The OTC company's December 20 call (SGP LD) has seen quite a bit of activity today. ... - Business Wire (press release),

Montelukast (Singulair) Added to Antihistamine or Corticosteroid ... Nov 11, 2005
...compared the antihistamine nasal spray azelastine (Astelin) in combination with montelukast to corticosteroid mometasone furoate (Nasonex) with montelukast. ... - DG News

ConsumersDiscountRx Pharmacy Affiliate Offers Levitra, an ... Nov 14, 2005
...a true destination for surfers specifically looking for secure prescription medications or allergy medications, such as allegra, clarinex, and nasonex from an ... - PR Web (press release),

Nasal Sprays Sep 24, 2005
Vancenase and Beconase (beclomethasone), Nasarel (flunisolide), Rhinocort (budesonide), Nasonex (mometasone), and Flonase (fluticasone), to name a few, can get ... - allergies.about.com

Beatle for sale: Paul McCartney and other pop stars have ... Sep 25, 2005
For a small fee, Lacuna Inc. will erase all memories of your partner ensuring eternal sunshine of the spotless mind.''. Nasonex, of course. ... - Boston Herald,

Research Shows Patients With Allergic Rhinitis Prefer NASONEX(R) ... Sep 6, 2005
Nearly twice the number of patients in the study indicated they would be more likely to use NASONEX daily as directed KENILWORTH, NJ, Sept. ... - PR Newswire (press release),

(HUG) - Confirmation of Interim Results date ... [+] Sep 6, 2005
...(PRN) - Research Shows Patients With Allergic Rhinitis Prefer NASONEX(R) (Mometasone Furoate Monohydrate) To Flonase(R) for Scent and Taste ... [+. ... - Bolsamania.com,

Other information

Indication
For the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older (as an inhalant). Also used as a cream/ointment for the relief of inflammatory and pruritic manifestations of dematoses.

Pharmacology
Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Corticosteroids have been shown to have a wide range of inhibitory effects on multiple cell types (e.g. mast cells, eosinophils, neutrophils, macrophages and lymphocytes) and mediators (e.g. histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation and in the asthmatic response. These anti-inflammatory actions of corticosteroids may contribute to their efficacy in asthma and in skin lesions.

Mechanism Of Action
Unbound corticosteroids cross cell membranes and bind with high affinity to specific cytoplasmic receptors. Inflammation is decreased by diminishing the release of leukocytic acid hydrolases, prevention of macrophage accumulation at inflamed sites, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A₂ inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Mometasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone.

Drug Category
Anti-allergic Agents; Anti-inflammatory Agents; ATC:D07AC13; ATC:D07XC03;

Brand Names/Synonyms
Asmanex Twisthaler; Combisor; Elocom; Elocon; Mometasone; Mometasone Furoate; Nasonex

Dosage Forms
CREAM; LOTION; METERED-DOSE (PUMP); OINTMENT

Absorption
Nasal spray is virtually undetectable in plasma

Interactions
Interactions for Mometasone:

In clinical studies, the concurrent administration of the ASMANEX^® TWISTHALER^® inhaler and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse events. However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing.

Chemical IUPAC Name
9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8, 11,12,

Chemical Formula
C22H28Cl2O4

Half Life
5.8 hours

Drug Type
Approved Drug

# Accession No
APRD00289

CAS Registry Number
105102-22-5